40 Trials, 2,722 Patients: Fecal Transplants Top the IBD Scorecard

If you've been told your Crohn's disease or ulcerative colitis flare is just inflammation to manage with pills, a new analysis suggests the bacteria living in your gut deserve just as much attention. Researchers pooled 40 randomized trials and more than 2,700 patients to answer a question many people with inflammatory bowel disease (IBD, the umbrella term for Crohn's disease and ulcerative colitis) have probably already asked their gastroenterologist: does deliberately changing your gut bacteria, through a fecal transplant, a probiotic pill, or something in between, actually put the disease into remission? For the first time, these options were ranked directly against each other in one statistical model, and the answer favors one clearly over the rest.

Key takeaways

• Fecal microbiota transplantation (FMT) was the only microbiome-based therapy that significantly improved both clinical remission and endoscopic remission (mucosal healing visible on colonoscopy), across a review of 40 trials and 2,722 IBD patients.
• Probiotics and synbiotics (a combination of probiotics and prebiotic fiber that feeds them) also beat placebo for clinical remission, just by a smaller margin, and neither showed a clear benefit for healing the gut lining itself.
• None of the therapies raised the odds of side effects or serious side effects.
• The FMT data carried a statistical inconsistency flag and this analysis is a preprint that has not yet been peer-reviewed, so the ranking should be read as directional, not final.

Fecal Transplants Ranked Highest for IBD Remission

FMT (fecal microbiota transplantation: transferring processed stool from a screened, healthy donor into a patient's colon to reset the gut's bacterial community) was the only microbiota-directed therapy that significantly improved both clinical and endoscopic remission, according to a new systematic review and network meta-analysis led by Hasnain Wajeeh Saqib and colleagues. A network meta-analysis is a statistical method that pools both head-to-head trial results and indirect comparisons, letting researchers rank several treatments against each other in a single model instead of relying on separate, disconnected studies. Patients who received FMT had roughly 2.8 times the odds of reaching clinical remission (symptoms dropping below a validated disease-activity threshold) compared with standard care, and a similar 2.8-fold increase in the odds of endoscopic remission, meaning the gut lining itself, not just symptoms, showed visible healing. Probiotics and synbiotics also beat standard care for clinical remission, with odds ratios around 2.3 and 2.6 respectively, but neither reached statistical significance for endoscopic remission.

Why Crohn's and Ulcerative Colitis Patients Should Care

IBD, which includes both ulcerative colitis and Crohn's disease, is a chronic, relapse-prone condition driven partly by a dysregulated immune response to the gut's own bacteria, and dysbiosis (an imbalanced, less diverse microbial community) shows up consistently in both forms of the disease. That mechanistic link is exactly why microbiome-directed treatments have moved from fringe idea to active research question over the past decade. For patients cycling through immunosuppressants and biologics, many of which carry their own side-effect burden, a therapy that works by restoring a healthier bacterial ecosystem is an appealing, different lever to pull.

40 Trials and 2,722 Patients Behind the Rankings

The review followed PRISMA-NMA guidelines (a reporting standard for network meta-analyses) and was prospectively registered on PROSPERO before the analysis began, a step that reduces the risk of researchers reshaping their outcomes after seeing the data. It combined 40 randomized controlled trials totaling 2,722 patients, ranging from small pilot studies of 10 to 12 participants to large multicenter trials exceeding 300, with follow-up periods from 4 to 104 weeks. Every trial was scored for risk of bias using the Cochrane RoB2 tool, and the results were not uniformly strong: only 4 of the 40 trials (10%) were rated low risk overall, 21 (52.5%) raised some concerns, and 15 (37.5%) were rated high risk, mostly because of open-label designs or unblinded outcome assessment.

What the Findings Mean for Your Treatment Conversations

For a reader managing Crohn's disease or ulcerative colitis, this study is a reason to ask a gastroenterologist where FMT fits into the current treatment picture, not a reason to seek it out independently. FMT for IBD remains an investigational approach studied mainly in specialized research and clinical settings, unlike its well-established use for recurrent C. difficile infection, and it is not a proven, generally available therapy the way biologics or immunosuppressants are. Probiotics and synbiotics, more accessible over-the-counter options, showed a real but modest remission benefit in this analysis, but the study pooled many different strains and formulations together, so it cannot tell you which specific product, dose, or combination would help an individual person. None of the interventions, including FMT, showed a significant increase in adverse events or serious adverse events, which is reassuring, though the researchers caution the safety data are too imprecise to rule out rarer harms.

The Inconsistency Problem Behind the FMT Numbers

The biggest asterisk on this study is a statistical check called node-splitting, which compares direct trial evidence against indirect evidence pieced together through the rest of the network. For FMT, the two didn't fully agree: direct trials showed a substantially larger benefit than indirect evidence implied, with the disagreement reaching statistical significance for FMT-versus-control (p = 0.03) and FMT-versus-probiotics (p = 0.03). That inconsistency suggests the FMT trials themselves may differ meaningfully in donor selection, delivery method, or patient severity. The antibiotics-plus-FMT combination, which had the single largest point estimate in the entire analysis, was built on data from just one small trial, and its wide statistical range crossed the line of "no effect" in the more conservative Bayesian model. This is also a preprint posted to Research Square, meaning it has not yet passed peer review.

What Comes Next for Microbiome-Based IBD Therapy

The study's authors call for larger, lower-bias trials that directly compare FMT-based regimens against single-agent probiotics and synbiotics, with standardized definitions of remission and consistent reporting of donor and strain details. Until those trials exist and this analysis clears peer review, the ranking is best treated as the current best guess rather than a settled hierarchy.

Common Questions

Is a fecal transplant available for IBD right now? Not as a standard, widely available treatment; it remains investigational for IBD specifically and is typically accessed through clinical trials or specialized centers, so ask your gastroenterologist whether you'd be a candidate for a study.

Do probiotics actually work for IBD? This analysis found a modest but statistically real benefit for clinical remission, though it didn't identify which specific strains or formulations drove that effect, so a doctor's guidance still matters more than a supplement aisle.

Is FMT safe? No treatment in this analysis, including FMT, showed a significant increase in adverse events, but the researchers note the safety data are too imprecise to rule out rare, serious risks like transmissible infection.

Why does this study say "preprint"? It means the analysis has been posted publicly but has not yet completed formal peer review, so its findings, while based on real trial data, could still be revised before publication in a journal.

References

1. Hasnain Wajeeh Saqib, Mujtaba Moazzam, Talha Khan, et al. (2026). Microbiota-Modifying Therapies for Inflammatory Bowel Disease: A Systematic Review and Bayesian Network Meta-Analysis. https://doi.org/10.21203/rs.3.rs-10292152/v1
2. NIDDK, ulcerative colitis overview. NIH. https://www.niddk.nih.gov/health-information/digestive-diseases/ulcerative-colitis
3. NIDDK, Crohn's disease overview. NIH. https://www.niddk.nih.gov/health-information/digestive-diseases/crohns-disease